Market Cap N/A
Revenue (ttm) 46.92M
Net Income (ttm) -38.10M
EPS (ttm) N/A
PE Ratio N/A
Forward PE 0.00
Profit Margin -81.20%
Debt to Equity Ratio N/A
Volume 775,700
Avg Vol 145,364
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 80%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
Zeppieddodaw
Zeppieddodaw Mar. 20 at 5:55 PM
$NGEN Interesting that market is dropping today and our stock is not. Thoughts?
2 · Reply
NVG291Fan
NVG291Fan Mar. 20 at 5:05 PM
$NGEN Based on today’s FDA news, I expect the next round of vouchers would be issued after this public hearing (if all goes well). Seems like great timing for us! https://www.fda.gov/news-events/press-announcements/fda-schedules-public-meeting-commissioners-national-priority-voucher-pilot-program
1 · Reply
Lytnup
Lytnup Mar. 20 at 4:51 PM
$NGEN After today, 7 business days left in Q1 - looking forward to hearing what the FDA has to say regarding: path(s) forward for NVG-291.
2 · Reply
MarianoItaliano
MarianoItaliano Mar. 20 at 6:33 AM
$NGEN growing back your nerves is such a scifi story and yet we have under 1k observers
0 · Reply
kenridge
kenridge Mar. 19 at 9:41 PM
$NGEN https://www.linkedin.com/posts/resilience-johnruffolo-neurotech-ugcPost-7440428724539338753-pgIs?utm_source=share&utm_medium=member_android&rcm=ACoAAACx73IBK4Uyo62WuQK57RayuesJsaIvfuQ
2 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 19 at 10:51 AM
$NGEN How many preclinical small cap biotech stocks do you know of that the DOD is doing research on their drug? I wouldn't be at all surprised that the FDA grants them accelerating approval for SCI. Then if the DOD study finds NVG-291 is effective for treating TBI we'll have a instant blockbuster on our hands. We could see a market cap of 30 to 50 billion in the next couple of years!
3 · Reply
NVG291Fan
NVG291Fan Mar. 19 at 10:46 AM
$NGEN This was a three-year award granted in August 2023. I have high hopes this combinatorial approach works:
1 · Reply
alexandredaigneault96
alexandredaigneault96 Mar. 19 at 1:19 AM
$NGEN shit is about to implode. Got a gut feeling it's coming. Hold on to your shares and don't sells buy more if you can. When you see on Fox News first ever drug for spinal cord injury approved stock price x15.
1 · Reply
Tarquinjones
Tarquinjones Mar. 19 at 12:58 AM
$NGEN did 200,000 shares trade after the close ???
1 · Reply
Eldorado_Toole
Eldorado_Toole Mar. 18 at 1:33 PM
$NGEN New online interview with CEO Rogers - BioTech Nation https://open.spotify.com/episode/5SRiXPpCK6DiA5ZUxeWgxR?si=Tpup1dD5Q3ibDCLxcTKuBQ&nd=1&dlsi=3077fbbf4b0c46f1
8 · Reply
Latest News on NGEN
NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 18, 2026, 7:30 AM EST - 4 weeks ago

NervGen Pharma to Participate at Upcoming Investor Conferences


NervGen Pharma Begins Trading on Nasdaq Today

Jan 8, 2026, 6:30 AM EST - 2 months ago

NervGen Pharma Begins Trading on Nasdaq Today


NervGen Pharma Announces Proposed Amendment to Warrants

Dec 12, 2025, 7:51 PM EST - 3 months ago

NervGen Pharma Announces Proposed Amendment to Warrants


NervGen Pharma: Risky, Yet Promising With Big Upside

Jun 13, 2025, 9:00 AM EDT - 10 months ago

NervGen Pharma: Risky, Yet Promising With Big Upside


NervGen Pharma Grants Stock Options

May 16, 2025, 4:30 PM EDT - 11 months ago

NervGen Pharma Grants Stock Options


NervGen Initiates Expanded Access Policy

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy


NervGen Pharma to Host Virtual Investor Event

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event


NervGen Announces "At-The-Market" Equity Program

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program


NervGen Pharma Appoints Neil Klompas to Board of Directors

Jul 22, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Appoints Neil Klompas to Board of Directors


Zeppieddodaw
Zeppieddodaw Mar. 20 at 5:55 PM
$NGEN Interesting that market is dropping today and our stock is not. Thoughts?
2 · Reply
NVG291Fan
NVG291Fan Mar. 20 at 5:05 PM
$NGEN Based on today’s FDA news, I expect the next round of vouchers would be issued after this public hearing (if all goes well). Seems like great timing for us! https://www.fda.gov/news-events/press-announcements/fda-schedules-public-meeting-commissioners-national-priority-voucher-pilot-program
1 · Reply
Lytnup
Lytnup Mar. 20 at 4:51 PM
$NGEN After today, 7 business days left in Q1 - looking forward to hearing what the FDA has to say regarding: path(s) forward for NVG-291.
2 · Reply
MarianoItaliano
MarianoItaliano Mar. 20 at 6:33 AM
$NGEN growing back your nerves is such a scifi story and yet we have under 1k observers
0 · Reply
kenridge
kenridge Mar. 19 at 9:41 PM
$NGEN https://www.linkedin.com/posts/resilience-johnruffolo-neurotech-ugcPost-7440428724539338753-pgIs?utm_source=share&utm_medium=member_android&rcm=ACoAAACx73IBK4Uyo62WuQK57RayuesJsaIvfuQ
2 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 19 at 10:51 AM
$NGEN How many preclinical small cap biotech stocks do you know of that the DOD is doing research on their drug? I wouldn't be at all surprised that the FDA grants them accelerating approval for SCI. Then if the DOD study finds NVG-291 is effective for treating TBI we'll have a instant blockbuster on our hands. We could see a market cap of 30 to 50 billion in the next couple of years!
3 · Reply
NVG291Fan
NVG291Fan Mar. 19 at 10:46 AM
$NGEN This was a three-year award granted in August 2023. I have high hopes this combinatorial approach works:
1 · Reply
alexandredaigneault96
alexandredaigneault96 Mar. 19 at 1:19 AM
$NGEN shit is about to implode. Got a gut feeling it's coming. Hold on to your shares and don't sells buy more if you can. When you see on Fox News first ever drug for spinal cord injury approved stock price x15.
1 · Reply
Tarquinjones
Tarquinjones Mar. 19 at 12:58 AM
$NGEN did 200,000 shares trade after the close ???
1 · Reply
Eldorado_Toole
Eldorado_Toole Mar. 18 at 1:33 PM
$NGEN New online interview with CEO Rogers - BioTech Nation https://open.spotify.com/episode/5SRiXPpCK6DiA5ZUxeWgxR?si=Tpup1dD5Q3ibDCLxcTKuBQ&nd=1&dlsi=3077fbbf4b0c46f1
8 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 18 at 10:17 AM
$NGEN There are so many drugs that receive FDA approval that are supported by data that is " clinically significant". Clinically significant should be call marginal at best. NVG-291 however show a clearly defined increase in motor function to those using the drug and no real adverse effects. Not to mention it is the first and only drug capable benefiting these patients. There is no reason that the FDA should deny this drug accelerated approval.
0 · Reply
DavesStockPicks
DavesStockPicks Mar. 17 at 7:43 PM
$NGEN That beautiful chart of NGEN on TradingView only has the recent Nasdaq information. I hope they apply the old data from TSXV trading information.
1 · Reply
alexandredaigneault96
alexandredaigneault96 Mar. 17 at 5:09 PM
$NGEN what will come up after FDA meeting which is this month? Neutral ? Bad news delays ? Good news ? What are the theories? Could be news that drives the stock up 100% or down 30% ? Comment below
8 · Reply
rubraquercus
rubraquercus Mar. 17 at 1:18 PM
$NGEN did everyone see this? Cozzarelli Prize: 15-PGDH blocks blood–brain barrier deterioration Interesting paper that was awarded the Cozzarelli Prize for the 2025 best paper in biological sciences by the National Academy of Sciences. https://www.pnas.org/doi/10.1073/pnas.2417224122 Significance Koh et al. show that 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is pathologically elevated in human and mouse Alzheimer’s disease (AD), traumatic brain injury (TBI), and aging, with 15-PGDH localized to myeloid cells of the blood–brain barrier (BBB). They further show that pharmacologic and genetic inhibition of 15-PGDH protects the BBB, blocks production of reactive oxygen species, prevents downstream neurodegeneration, and preserves cognition in mouse models of AD and TBI. Thus, 15-PGDH inhibition represents a therapeutic approach for AD and TBI by protecting the BBB.
1 · Reply
aladdinscarpet
aladdinscarpet Mar. 16 at 11:09 PM
$NGEN Could not resist adding at these insane sale prices. Uplist now complete. Counting down by the day to substantial news updates which are likely to rerate valuation in a substantial way. This is a unique opportunity to own a neurology franchise for less than 1% of its eventual value…make sure you act accordingly!!
3 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 16 at 7:26 PM
$NGEN FDA meeting any day now. It will only confirm what we already know. Very strong data!
0 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 15 at 7:37 PM
1 · Reply
KGEEEZY
KGEEEZY Mar. 15 at 2:06 PM
$NGEN If we get news that NGEN has received Accelerated Access this stock is MOOOOONING!!!
2 · Reply
DavesStockPicks
DavesStockPicks Mar. 14 at 12:33 AM
$NGEN We're still in an upward trend. It'll soon test the moving average here soon and we'll have confirmation if that trend will continue or not.
1 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 14 at 12:25 AM
$NGEN Can anyone speak to NGEN leadership? Anything noteworthy? Reason I ask is it looks like they've been shuffling the deck a little.
0 · Reply
TH3_PR0F1T
TH3_PR0F1T Mar. 13 at 11:27 PM
$NGEN End of Phase 2 FDA meeting very soon.
2 · Reply
Eldorado_Toole
Eldorado_Toole Mar. 13 at 9:09 PM
$NGEN Need to watch a video, it'll make you feel better... "222 seconds to 21 seconds" https://vimeo.com/1139656943/8028c1f465?fl=pl&fe=sh
4 · Reply